Cisapride (R 51619): Mechanistic Insights for Cardiac Electrophysiology Research

Executive Summary: Cisapride (R 51619) is a nonselective 5-HT4 receptor agonist and a potent hERG potassium channel inhibitor, with high purity (99.70%) and solubility in DMSO (≥23.3 mg/mL) and ethanol (≥3.47 mg/mL), but insoluble in water. It is widely adopted in cardiac electrophysiology research and predictive cardiotoxicity screening, especially using iPSC-derived cardiomyocyte models (Grafton et al., 2021, DOI). The compound’s dual action enables detailed interrogation of 5-HT4 receptor signaling and hERG channel inhibition—key pathways in arrhythmia and drug safety studies. Deep learning and high-content phenotypic screens have validated its predictive value for cardiotoxic liabilities. Proper storage at -20°C and avoidance of long-term solution storage are critical for experimental integrity (product page).

Biological Rationale

Cisapride (R 51619) is employed in research to probe cardiac and gastrointestinal physiology. The compound’s activity as a nonselective 5-HT4 receptor agonist enables the study of serotonergic signaling in gastrointestinal motility and cardiac tissue. Its potent inhibition of the human ether-à-go-go-related gene (hERG) potassium channel provides a direct tool for modeling arrhythmogenic risk in vitro. Cardiotoxicity is a leading cause of drug attrition, with approximately one-third of withdrawals linked to adverse cardiac events (Guo et al., 2011; DOI). In vitro human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) have emerged as a gold standard for modeling human cardiac electrophysiology and detecting drug-induced liabilities (Maddah et al., 2020; DOI).

Mechanism of Action of Cisapride (R 51619)

Cisapride acts as a nonselective agonist at 5-HT4 receptors. These G protein-coupled receptors modulate gastrointestinal motility and cardiac electrophysiology through cAMP-mediated pathways. In parallel, Cisapride inhibits the hERG (KCNH2) potassium channel, which is crucial for cardiac action potential repolarization. hERG inhibition leads to delayed ventricular repolarization, manifesting as QT prolongation and increased risk of arrhythmia. The compound’s dual mechanism supports its use as a probe in both gastrointestinal and cardiac models. Chemically, Cisapride is 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide, with a molecular weight of 465.95 g/mol (product page).

Evidence & Benchmarks

• Cisapride (R 51619) induces dose-dependent hERG current inhibition in both heterologous expression systems and iPSC-derived human cardiomyocytes (Grafton et al., 2021, DOI).
• At concentrations as low as 10 nM, Cisapride significantly prolongs action potential duration in iPSC-CMs, correlating with clinical QT interval effects (Grafton et al., 2021, Table 2, DOI).
• High-content phenotypic screens using deep learning identify Cisapride as a robust and reproducible positive control for arrhythmogenic risk profiling (DOI).
• Cisapride is highly soluble in DMSO (≥23.3 mg/mL) and ethanol (≥3.47 mg/mL), but insoluble in water, which defines handling and assay conditions (product page).
• Batch quality is verified via HPLC, NMR, and MSDS documentation, with certified purity of 99.70% (product page).

For more comparative and mechanistic details, see this article, which details the integration of Cisapride in deep learning-driven phenotypic workflows. This current article extends that discussion by providing up-to-date, citation-rich benchmarks and clarifying storage and handling boundaries.

Applications, Limits & Misconceptions

Cisapride (R 51619) is primarily used in research settings to:

• Model arrhythmogenic risk in cardiac electrophysiology studies.
• Serve as a positive control for hERG channel inhibition in safety pharmacology screens.
• Probe 5-HT4 receptor-mediated signaling in gastrointestinal motility research.
• Integrate with iPSC-derived cardiomyocyte workflows for predictive toxicology (DOI).

For a strategic overview, see this article, which focuses on workflow optimization; the current piece adds evidence benchmarks and clarifies compound stability for translational research.

Common Pitfalls or Misconceptions

• Cisapride is not water-soluble: It must be dissolved in DMSO or ethanol for use; aqueous buffers result in poor solubility and inconsistent dosing (product page).
• Long-term storage in solution is not advised: Prepare fresh aliquots from solid stock for each use to avoid degradation and loss of potency.
• Not selective for hERG only: As a nonselective 5-HT4 receptor agonist, Cisapride may affect serotonergic pathways beyond hERG inhibition.
• Clinical use discontinued: Cisapride is not approved for human therapeutic use due to arrhythmia risk, and should only be used in laboratory research (FDA withdrawals, FDA database).
• Requires precise dosing: Cardiac phenotypes can be highly dose-dependent; always calibrate concentrations using positive control data.

Workflow Integration & Parameters

Cisapride (R 51619) is supplied as a solid and should be stored at -20°C in a desiccated environment. For experimental use, dissolve in DMSO or ethanol at the required stock concentration. Typical working concentrations for cardiac electrophysiology assays range from 1 nM to 10 µM, depending on the model system and endpoint. For iPSC-cardiomyocyte screens, use validated concentration-response curves and parallel vehicle controls (DOI). Avoid freeze-thaw cycles and prepare aliquots to maintain compound integrity. For detailed troubleshooting and workflow strategies, see this article, which offers mechanistic guidance; the present article further contextualizes quality control and stability parameters.

Conclusion & Outlook

Cisapride (R 51619) remains a benchmark research tool for dissecting cardiac electrophysiology, hERG channel inhibition, and 5-HT4 receptor signaling. Its proven compatibility with iPSC-derived cardiomyocyte assays and deep learning-driven phenotypic screens makes it indispensable for predictive toxicology and translational drug safety workflows (DOI). Ongoing integration with high-content screening platforms will further refine its role in early-stage drug discovery and mechanistic research. For reagent specifications and up-to-date documentation, consult the B1198 kit product page.